Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 4148 全宇生技-KY. Please read: https://finlab.finance/en/setup?stock=4148

No install, open FinLab Studio

4148

全宇生技-KY Biotech & Healthcare As of 2026-06-17 Updated daily after market close

steady quality, discounted valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 全宇生技-KY to your watchlist to track signal changes on your next visit.
Valuation 77Quality 37Growth 66Momentum 8Chips 56

Is 全宇生技-KY a buy? Fundamentals and valuation first

  • Above-average profitability.Operating margin is in the 45th market percentile. Latest quarterly ROE ≈ 0.4%.

  • Valuation is low.PE is in the 23th market percentile; within its own history, PE is around the 23th percentile.

  • Foreign investors are net buying.Foreign 20-day net flow ≈ 1.2% of volume (net buy).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 21.8%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Bullish +0.33
BearishNeutralBullish

Single-sided accumulation, concentration rising — bullish

  • Single-sided accumulation, concentration rising — bullish
  • 兆豐-公益 holds 314 lots
  • sellers have 34 lots left, ~40 sessions to clear

Window from 2026-01-17 · Price -19% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 兆豐-公益 has accumulated 314 lots since the start (sold 0%), holding.
  • Main distributor 富邦-嘉義 peaked at 50 lots, has sold 64%, 18 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders +0.10pp, mid holders +1, retail -0.11pp — concentration shifting upward.
  • Foreign hedge-desk net short Net short -130 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
兆豐-公益兆豐-復興臺銀-新竹第一金-路竹華南永昌-台中凱基-站前
Distributing
富邦-嘉義凱基-三多富邦-台北凱基-市府元大-發財台新-台南
Desks
own scale
中國信託-高雄兆豐證券國泰-松江富邦證券
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 兆豐-公益 +314
    sold 0%
  • 兆豐-復興 +232
    sold 0%· still adding
  • 臺銀-新竹 +113
    sold 0%
  • 第一金-路竹 +107
    sold 0%· still adding
  • 華南永昌-台中 +103
    sold 2%
  • 凱基-站前 +83
    sold 1%

Distributing

  • 富邦-嘉義 18 left
    sold 64%· paused recently
  • 凱基-三多 24 left
    sold 37%· paused recently
  • 富邦-台北 14 left
    sold 53%· ~23 sessions to clear
  • 凱基-市府 10 left
    sold 50%· paused recently
  • 元大-發財 11 left
    sold 27%· paused recently
  • 台新-台南 2 left
    sold 85%· paused recently

Desks

  • 中國信託-高雄 -156
    unclassified
  • 兆豐證券 -140
    unclassified
  • 國泰-松江 -117
    unclassified
  • 富邦證券 -100
    unclassified
Still selling 34 lots ~40 sessions to bottom at most
Recent buy/sell force +142 absorbed / -22 sold buyers slightly ahead
Hedge-desk net short -58 lots potential cover-buying, not selling pressure
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Direction matches: big-holder share rose while retail share fell.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 21.75%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

45 historical occurrences (since 2017-08-10)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 47.7%, Sample 44, Median -0.89%, Excess +0.96%, Beat mkt rate 38.6%；60-day: Win 44.2%, Sample 43, Median -2.98%, Excess -4.04%, Beat mkt rate 39.5%；120-day: Win 37.2%, Sample 43, Median -6.29%, Excess -9.18%, Beat mkt rate 25.6%

120 days after: historical avg -1.49%

20-day +2.56%
60-day -0.52%
120-day -1.49%
20-day
60-day
120-day
Win
47.7%
44.2%
37.2%
Sample
44
43
43
Median
-0.89%
-2.98%
-6.29%
Excess
+0.96%
-4.04%
-9.18%
Beat mkt rate
38.6%
39.5%
25.6%

Over 43 occurrences, 120-day forward avg declined 1.49%, lagged the market by 9.18 pts; win rate 37.2%.

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 299-8.9% -13.4% 20.4% -39.8%
20-40 You are here282+45.6% +45.3% 82.3% +46.5%
40-60 104+1.6% -2.7% 38.5% -30.4%
60-80 300+4.7% -8.5% 25% -18.9%
80-100 2210% -3.8% 38.9% -30.8%

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 14.42, at the 23.4th percentile of its own history (20-40 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation
Momentum
Cheap (own-history bottom 1/3)
Mid
Expensive (own-history top 1/3)
60-day momentum up
+8.4%
Win rate 49.7% Excess +2.8%
173d
+21%
Win rate 58.4% Excess +15.6%
226d
-7.6%
Win rate 16.4% Excess -18.6%
220d
60-day momentum down
Now
+7.2%
Win rate 68.5% Excess -4.2%
308d
-3.9%
Win rate 40.9% Excess -35.5%
164d
-2.2%
Win rate 29.4% Excess -14.7%
228d

Currently in “Cheap (own-history bottom 1/3) × 60-day momentum down”: across 308 historical days, 120-day forward avg gained 7.2%, win rate 68.5%, lagged the market by 4.2%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

33 times historically; 60-day forward avg -5.1%, win rate 33.3%, beating the market by -9.11 pts on average.

What does 全宇生技-KY do? Company profile

生技醫療業；農業生技、微生物生化複合肥料、保健食品 台灣證券交易所上市

Overview

4148 對應證券為全宇生技-KY，屬台灣證券交易所上市普通股。公司全名為全宇生技控股有限公司，英文名 All Cosmos Bio-Tech Holding Corporation，於 2010 年 3 月 26 日在開曼群島註冊成立，2017 年 6 月 8 日在台灣證交所第一上市。主要營運基地在馬來西亞，台灣訴訟及非訟代理人聯絡處為台北市松山區復興北路181號7樓之4；董事長兼總經理為彭士豪，發言人為石景薇。公開資料顯示 2026 年 6 月附近實收資本額約新台幣 6.72 億元、已發行普通股約 6,723.57 萬股；較早 Yahoo 基本資料仍列股本 640,340,010 元、已發行普通股 64,034,001 股，應與後續股本變動或資料時間差異有關。主要股東公開資料包含 All Cosmos Investment Ltd.、Oil Palm Plantation Ltd. 及經營團隊相關持股；第三方資料亦列員工約 554 人，但此員工數未能以最新年報直接核對。

Business

公司核心是以有益微生物技術應用於農業生技，旗下全宇工業 All Cosmos Industries Sdn. Bhd. 為主要營運子公司。主要產品為結合有機質、微生物及化學原料的三合一生化複合肥料，並銷售微生物有機複合肥、化學肥料、植物疫苗/病害防治相關產品及保健食品。自有品牌為 RealStrong 大壯牌，銷售模式包括大型標案、專案銷售與市場零售，主要客戶為馬來西亞及東南亞的政府關係企業、大型民營油棕種植集團、經銷商與基層農戶，主要終端作物為油棕，亦延伸至水果、胡椒、稻米、橡膠等作物。2025 年產品組合公開年報整理顯示：生化複合肥料新台幣 1,811,400 仟元、佔 61.42%；化學肥料 656,789 仟元、佔 22.27%；其他 480,834 仟元、佔 16.30%。2025 年全年累計營收約新台幣 2,949,023 仟元或第三方月營收表列 2,952,991 仟元，年增約 15.7% 至 19.2%，差異可能來自公告口徑或資料擷取時間。保健食品方面，2019 年與葡萄王合作於馬來西亞成立 GK BIO，布局東協保健品通路，法說摘要指出線下通路約 1,800 間，保健食品為第二成長曲線。

Outlook 2025–2028

2025 至 2028 年主要成長動能包括：一、馬來西亞油棕市場施肥剛性需求及 ESG/低碳農業要求推升生化複合肥料比重，公司 2025 年生化複合肥料佔比已提升至約 61%，法說摘要稱 2025 Q3 曾達 63.78%，公司目標回升至歷史高點約 65% 至 70%。二、印尼新廠與印尼市場拓展；2024 年報原規劃印尼廠初期年產能 5 萬噸，2025 年年報整理與法說摘要指出印尼廠已於 2025 年取得銷售相關執照，預計 2026 年起正式貢獻營收，長期可降低跨境運輸與稅務成本並切入全球最大棕櫚種植市場。三、保健食品業務以 GK BIO 及東協通路延伸為第二成長曲線，公開法說摘要稱維持雙位數成長，並規劃從華人市場延伸至穆斯林市場、越南等區域。四、循環經濟與植物疫苗/功能醣：公司以油棕空果串、果泥等農業廢棄物高值化，推動有機資材、植物疫苗及油棕資材轉化醣類技術。主要風險包括油棕價格循環影響種植園施肥意願、尿素/磷礦粉/氯化鉀等肥料原料價格波動、馬來西亞與印尼法規及產品登記進度、匯率、氣候水患與齋戒月等季節性出貨干擾、化肥廠削價競爭、印尼新廠產能利用率爬坡不如預期，以及保健食品跨國通路與法規認證不確定性。2027 至 2028 年未見公司提供明確量化財測，以上為根據公開年報、法說與產業趨勢的定性推估。

Supply Chain

Upstream
  • 肥料原料供應商（未揭露具名） 上游原料包含尿素、磷礦粉、氯化鉀、硼砂、磷酸銨、氯化銨、白雲石粉及可可殼渣、咖啡渣、油棕子渣等有機質；公開資料未確認具名供應商，多為國際或馬來西亞原料供應鏈。
  • Sawit Kinabalu Group 馬來西亞沙巴州政府旗下油棕集團，公開資料稱與全宇相關子公司共同投入油棕廢棄物處理再利用，屬循環經濟有機資材來源及合作夥伴，非台股掛牌。
  • Sabah Softwoods Berhad 馬來西亞油棕/林業相關企業，與全宇相關公司成立 Sabah Softwoods Hybrid Fertiliser Sdn. Bhd.，屬東馬沙巴廠、油棕資材及在地通路合作夥伴，非台股掛牌。
  • YPJ Plantations Sdn. Bhd. 馬來西亞柔佛州政府相關種植公司，公開資料稱與全宇合作設立印尼新廠，屬印尼產能與在地化布局合作夥伴，非台股掛牌。
  • 葡萄王生技股份有限公司 1707 與全宇生技及專業經理人於馬來西亞成立合資公司布局東協保健食品市場；屬保健食品研發、品牌與通路合作夥伴，非肥料原料供應商。
Downstream
  • 馬來西亞政府關係企業與大型油棕種植園 主要肥料客戶群，透過標案及專案銷售採購生化複合肥料；多數為馬來西亞國營或民營大型種植企業，非台股掛牌。
  • Kuala Lumpur Kepong Berhad（KLK） 公開資料列為可能客戶例示之一，為馬來西亞上市大型種植企業，非台股掛牌；客戶關係及採購金額未見最新年報具體揭露。
  • Sawit Kinabalu Group 公開資料列為油棕種植相關客戶/合作夥伴之一，可能同時具下游客戶與上游資材合作角色，非台股掛牌。
  • 東南亞肥料經銷商與基層農戶 公司產品銷往馬來西亞、菲律賓、印尼、越南等地，透過經銷與市場銷售觸及中小型種植園及農民。
  • GK BIO 保健食品通路與終端消費者 保健食品業務下游，公開法說摘要稱線下約 1,800 間通路並搭配線上行銷；GK BIO 為合資公司，非台股掛牌。

Competitors

  • 台灣肥料股份有限公司 1722 台股上市肥料及化工公司，與全宇在肥料與農業資材領域有部分競爭，但台肥主市場與產品結構不同。
  • 興農股份有限公司 1712 台股上市農藥、肥料、農業資材及通路公司，與全宇在農業投入品市場有競爭或替代關係。
  • 惠光股份有限公司 6508 台股上櫃農藥及特殊化學品公司，與全宇在作物保護及農業資材市場有部分競爭。
  • 正瀚生技股份有限公司 6534 台股創新板農業生技公司，投入植物生長調節、微生物與農業生技相關產品，與全宇在農業生技應用方向具可比性。
  • Yara International ASA 挪威上市全球肥料公司，非台股掛牌；在化學肥料及作物營養市場為國際競爭者。
  • Nutrien Ltd. 加拿大/美國上市全球肥料與農業零售龍頭，非台股掛牌；在鉀肥、氮肥及作物營養市場為國際競爭者。
  • 馬來西亞及印尼當地化肥廠商 公開年報提到化肥廠商削價競爭會影響接單與產品組合；多數未具名且非台股掛牌。
Sources（17）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.